New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
09:06 EDTSNYArdelyx licenses NaP2b phosphate inhibitor program to Sanofi
Ardelyx announced that it has licensed to Sanofi its novel phosphate transport NaP2b inhibitor program,also known as NaPi2b, Npt2b and SLC34A2. Ardelyx will receive an undisclosed upfront payment from Sanofi. Total development and regulatory milestones could potentially reach up to $198M. Ardelyx would also be entitled to royalties on product sales. In addition, Ardelyx retains an option to participate in co-promotional activities for the U.S. market.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use